PhaseBio Pharmaceuticals Inc License Agreements
7 Contracts & Agreements
- Acknowledgement of Grant of a Sublicense in Accordance with the License Agreement between Medimmune Limited and PhaseBio Pharmaceuticals, Inc. and Related Options (Filed With SEC on August 12, 2021)
- License Agreement, dated as of June 16, 2021, by and between PhaseBio Pharmaceuticals, Inc. and Alfasigma, S.p.A (Filed With SEC on August 12, 2021)
- Amendment to License Agreement, dated January 9, 2020, by and between PhaseBio Pharmaceuticals, Inc. and MedImmune Limited (Filed With SEC on March 30, 2020)
- License Agreement, dated April 1, 2019, by and between PhaseBio Pharmaceuticals, Inc. and Wacker Biotech GmbH (Filed With SEC on April 9, 2019)
- Eighth Amendment to License Agreement, dated as of March 5, 2019, by and between PhaseBio Pharmaceuticals, Inc. and Duke University (Filed With SEC on April 9, 2019)
- License Agreement, dated as of November 21, 2017, by and between the Registrant and Medimmune Limited (Filed With SEC on September 21, 2018)
- License Agreement, dated as of October 18, 2006 and as amended to date, by and between Phase Bioscience, Inc. (predecessor in interest to the Registrant) and Duke University (Filed With SEC on September 21, 2018)
